세계의 인공임신중절약 시장 : 약제 클래스별, 유통 채널별, 예측(2024-2032년)

Global Abortion Drugs Market Size will grow at 8.2% CAGR during 2024-2032, driven by technological breakthroughs leading to the development of safer and more effective abortion drugs., rising demand for convenient and non-invasive abortion methods, and changing socio-cultural norms regarding reproductive health.

One of the primary growth drivers for the market is the increasing demand for safe and accessible abortion options globally. For instance, according to WHO, by 2030, the SDG for women's reproductive health aims to achieve universal access to comprehensive sexual and reproductive healthcare services, encompassing family planning, education, and the seamless integration of reproductive health into national strategies. As awareness about reproductive health and rights continues to grow, individuals seek out safe and effective methods for managing unplanned pregnancies. Abortion drugs offer a non-invasive and convenient alternative to surgical procedures, providing women with greater autonomy over their reproductive choices. Additionally, factors such as changing socio-cultural norms, advancements in medical technology, and expanding healthcare infrastructure contribute to the rising demand for abortion drugs.

The Abortion Drugs Market is classified based on drug class, distribution channel, and region.

The hemabate segment will record a healthy valuation by 2032, owing to the effectiveness of hemabate in inducing uterine contractions, which makes it a preferred choice for healthcare providers. This mechanism, coupled with its safety profile and high success rates, positions Hemabate as a frontline treatment option for women seeking non-surgical abortion procedures, particularly in the second trimester.

The abortion drugs market share from the online pharmacies segment will grow substantially over 2024-2032. The convenience, privacy, and accessibility offered by online platforms have made them popular among consumers seeking abortion medications. Besides, the proliferation of online pharmacies could drive significant sales of abortion drugs, contributing to market growth.

Asia Pacific Abortion Drugs Industry will exhibit tremendous growth through 2032, driven by increasing awareness about reproductive rights, improving healthcare infrastructure, and rising healthcare expenditure. Countries like China, India, and South Korea could lead the market expansion in the region due to large populations and changing socio-cultural norms regarding reproductive health. As disposable incomes increase and healthcare becomes a priority, individuals are more willing to invest in their well-being. This shift in healthcare spending patterns directly correlates with an increased demand for a range of medical services, including reproductive health services, thereby contributing to industry expansion.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast calculations
• 1.5 Data validation
• 1.6 Data sources
  • 1.6.1 Primary
  • 1.6.2 Secondary
    • 1.6.2.1 Paid sources
    • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of unplanned pregnancies
    • 3.2.1.2 Increasing focus on women's reproductive rights
    • 3.2.1.3 Advancements in medical technology
    • 3.2.1.4 Increasing awareness and education
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Social and cultural stigma
    • 3.2.2.2 High cost and side-effects associated with certain drugs
    • 3.2.2.3 Stringent regulatory environment
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Mifepristone
• 5.3 Misoprostol
• 5.4 Pitocin
• 5.5 Hemabate
• 5.6 Carboprost
• 5.7 Other drug classes

Chapter 6 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Hospital pharmacies
• 6.3 Retail pharmacies
• 6.4 Online pharmacies

Chapter 7 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 North America
  • 7.2.1 U.S.
  • 7.2.2 Canada
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 France
  • 7.3.4 Spain
  • 7.3.5 Italy
  • 7.3.6 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 Japan
  • 7.4.2 China
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 South Korea
  • 7.4.6 Rest of Asia Pacific
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Mexico
  • 7.5.3 Argentina
  • 7.5.4 Rest of Latin America
• 7.6 Middle East and Africa
  • 7.6.1 South Africa
  • 7.6.2 Saudi Arabia
  • 7.6.3 UAE
  • 7.6.4 Rest of Middle East and Africa

Chapter 8 Company Profiles

• 8.1 Cipla Limited
• 8.2 Endo International plc
• 8.3 Exelgyn
• 8.4 Gedeon Richter plc
• 8.5 Jubilant Life Sciences
• 8.6 Lupin Limited
• 8.7 Mylan N.V.
• 8.8 Pfizer Inc.
• 8.9 Sun Pharmaceutical Industries
• 8.10 Torrent Pharmaceuticals Ltd.
• 8.11 Zydus Lifesciences Limited